As hearing healthcare professionals, your clinical decisions are guided by experience and evidence. To support your practice, Cochlear is proud to share the latest reliability reports for the Nucleus® System and Osia® System which offer transparent, standards-based insights into device performance across implantable and external components.
Key Highlights:
- Nucleus® System
- Over 600,000 registered implants analyzed
- Up to 99.8% Cumulative Survival Percentage (CSP) within 5 years for current-generation implants
- Sound processor reliability measured by Failed Component Return Rate (FCRR), with rates as low as 0.3%
- Osia® System
- Piezoelectric bone conduction technology designed for long-term performance
- OSI300 Implant: 99.86% CSP within 1 year
- OSI200 Implant: 99.64% CSP within 5 years
- Osia 2/2(I) Sound Processor: 0.3% average FCRR over 24 months
Both reports adhere to internationally recognized standards including ISO 5841-2, the European Consensus Statement, and ANSI/AAMI CI86, ensuring the data is clinically robust and globally aligned.
Whether you’re selecting an implant for a pediatric candidate, managing long-term follow-up, or counseling patients on device performance, these reports provide the clarity and confidence you need to support optimal outcomes.
View the Cochlear Nucleus System Reliability Report:
View the Cochlear Osia System Reliability Report:
